NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.
News|Articles|July 17, 2026
Hereditary Hemochromatosis: A Preventable Burden Hidden in Plain Sight
Author(s)Maggie L. Shaw
Fact checked by: Laura Joszt, MA
A common, underdiagnosed genetic disorder, hereditary hemochromatosis is costly when caught late and simple to treat when caught early.
Advertisement
Advertisement
One of the most common inherited genetic disorders in the US is quietly driving cirrhosis, heart failure, and diabetes as well as years of unnecessary specialist care, all largely preventable with a blood test and a timely diagnosis, according to Usha Perepu, MD, a nationally recognized classical hematology expert and director of classical hematology at the Mays Cancer Center at UT Health San Antonio.
Related to this article
North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
The IRA's Medicare out-of-pocket cap is easing costs for patients with cancer, but community oncology leaders warn price cuts are straining practices.
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
Advertisement
Advertisement